Clinical trial readout dates for Erasca Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2028.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 1/2 ERAS-007 Advanced or Metastatic Solid Tumors · NCT04866134 | July 2026 Primary data collected |
| Phase 3 Naporafenib Advanced or Metastatic NRAS-mutant Melanoma · NCT06346067 | April 2028 Ongoing |
Erasca Inc. reported $1.25B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $51M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-12 |